Sarepta Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SRPT in the last 7 days.
No SEC Form 4 filings for $SRPT in the last 30 days.
See all $SRPT insider activity →Sarepta Therapeutics' INSIGHTT trial has begun testing SRP-1005, an experimental HTT-lowering drug for Huntington's disease. The trial aims to evaluate the safety and delivery method of SRP-1005, which is administered via subcutaneous injection. The study involves 32 participants and is expected to run through late 2027.
Sarepta Therapeutics rose 8.6% to $19.57 on Wednesday, driven by a broad biotech sector rally. Peer companies RXRX, TSHA, AGIO, DMRA, and SNDX also posted gains. The move reflects broader sector sentiment rather than company-specific news, with Sarepta's market cap now at $2.1 billion.
Sarepta Therapeutics reported Q2 2026 net product revenue of $328.7M, with GAAP operating income of $13.3M and non-GAAP operating income of $86.5M. The company appointed Michael Severino as CEO and narrowed its 2026 revenue guidance to $1.2B-$1.3B. Sarepta's pipeline includes treatments for Duchenne muscular dystrophy (DMD) and other rare diseases, with key data readouts expected in the second half of 2026. Analysts have mixed ratings and price targets for the company.
Recent SRPT coverage spans earnings, financial news and technology.
Early‑stage trial start may affect SRPT sentiment but no immediate commercial impact.
The stock jumped on sector momentum without a company‑specific catalyst.
Earnings beat on operating profit and guidance raise suggest near‑term upside potential.
Guidance tightening plus pipeline progress frames a near-term valuation reset, but safety and cost risks keep upside capped.
Guidance narrowing plus sharply lower YoY revenue and EPS suggests near-term earnings pressure, partially offset by higher Roche-related collaboration expectations and cash build.
alphai scores every news story that mentions SRPT with an AI model for sentiment and relevance, and aggregates insider trades from Sarepta Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sarepta Therapeutics' INSIGHTT trial has begun testing SRP-1005, an experimental HTT-lowering drug for Huntington's disease. The trial aims to evaluate the safety and delivery method of SRP-1005, which is administered via subcutaneous injection. The study involves 32 participants and is expected to run through late 2027.
2 min readSarepta Therapeutics rose 8.6% to $19.57 on Wednesday, driven by a broad biotech sector rally. Peer companies RXRX, TSHA, AGIO, DMRA, and SNDX also posted gains. The move reflects broader sector sentiment rather than company-specific news, with Sarepta's market cap now at $2.1 billion.
1 min readSarepta Therapeutics reported Q2 2026 net product revenue of $328.7M, with GAAP operating income of $13.3M and non-GAAP operating income of $86.5M. The company appointed Michael Severino as CEO and narrowed its 2026 revenue guidance to $1.2B-$1.3B. Sarepta's pipeline includes treatments for Duchenne muscular dystrophy (DMD) and other rare diseases, with key data readouts expected in the second half of 2026. Analysts have mixed ratings and price targets for the company.
2 min readSimply Wall St reports Sarepta Therapeutics (SRPT) narrowed its 2026 total net product revenue guidance to $1.2b to $1.3b alongside Q2 results and pipeline updates. The article cites a consensus price target of $21.65 versus a $18.38 last close, with analyst targets ranging from $5.0 to $38.0, and notes ELEVIDYS safety and high R&D costs as risks.
6 min readSarepta Therapeutics (SRPT) reported Q2 2026 results on an earnings call. Total revenue was $401.3M, down 34% YoY, with net product revenue $328.7M. Non-GAAP diluted EPS was $0.64. Cash and investments rose to $945.0M. 2026 product revenue guidance was narrowed to $1.2B-$1.3B, and Roche milestone and collaboration revenue were discussed.
7 min readState Street Corporation and affiliate SSGA Funds Management filed Schedule 13G disclosures for Sarepta Therapeutics. State Street reports 8,916,103 shares, 8.4% of the class, with shared voting power of 8,642,126 and shared dispositive power of 8,916,103. SSGA Funds Management reports 6,285,547 shares, 6%.
2 min readSarepta Therapeutics reported GAAP and non-GAAP operating profitability and said ELEVIDYS commercial execution improved enrollment forms. It narrowed 2026 total net product revenue guidance to $1.2B-$1.3B and expects second-half revenue modestly lower. The company recorded a $39M litigation contingency and raised collaboration/other revenue guidance by $75M on higher Roche contract manufacturing. Interim MAD results for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in H2 2026.
7 min readSarepta Therapeutics appointed Michael Severino as CEO effective July 28, replacing Doug Ingram. The change comes as Elevidys faced FDA label restrictions tied to liver safety signals and Sarepta reported Q1 revenue of $730.8 million, down from about $745 million year over year, citing lower Elevidys volumes. FDA decision dates for Amondys 45 and Vyondys 53 are set for Feb. 28, 2027.
5 min readSarepta Therapeutics (SRPT) reported Q2 2026 adjusted EPS of 64 cents vs 58 cents expected, though down 68% YoY. Revenues were $401.3M, down 34% YoY, beating the $355.6M estimate, mainly due to lower Elevidys sales. SRPT narrowed 2026 net product revenue guidance to $1.2-$1.3B and raised collaboration revenue to $550-$600M. FDA accepted filings for full approvals of Vyondys 53 and Amondys 45.
7 min readSarepta Therapeutics (NASDAQ:SRPT) said it will appoint Michael Severino, M.D., as chief executive officer effective July 28, 2026. The company said Severino previously served as CEO of Tessera Therapeutics and will join Sarepta’s board. The change may affect company strategy and leadership going forward.
2 min read
